CTI BioPharma Corp. (CTIC): Price and Financial Metrics

CTI BioPharma Corp. (CTIC): $1.98

0.08 (+4.21%)

POWR Rating

Component Grades













Add CTIC to Watchlist
Sign Up

Industry: Biotech


of 450

in industry

CTIC Stock Summary

  • CTIC's price/sales ratio is 106.6; that's higher than the P/S ratio of 97.46% of US stocks.
  • As for revenue growth, note that CTIC's revenue has grown -85.92% over the past 12 months; that beats the revenue growth of just 1.47% of US companies in our set.
  • The volatility of Cti Biopharma Corp's share price is greater than that of 94.89% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Cti Biopharma Corp, a group of peers worth examining would be VXRT, BCYC, EPZM, QUIK, and KIN.
  • Visit CTIC's SEC page to see the company's official filings. To visit the company's web site, go to www.ctibiopharma.com.

CTIC Stock Price Chart Interactive Chart >

Price chart for CTIC

CTIC Price/Volume Stats

Current price $1.98 52-week high $4.13
Prev. close $1.90 52-week low $1.43
Day low $1.88 Volume 1,345,706
Day high $2.04 Avg. volume 1,472,368
50-day MA $2.19 Dividend yield N/A
200-day MA $2.49 Market Cap 191.45M

CTI BioPharma Corp. (CTIC) Company Bio

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The company was founded in 1991 and is based in Seattle, Washington.

CTIC Latest News Stream

Event/Time News Detail
Loading, please wait...

CTIC Latest Social Stream

Loading social stream, please wait...

View Full CTIC Social Stream

Latest CTIC News From Around the Web

Below are the latest news stories about Cti Biopharma Corp that investors may wish to consider to help them evaluate CTIC as an investment opportunity.

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on January 5, 2022, in accordance w

Yahoo | January 6, 2022

CTI BioPharma: Long And Troubled History, Finally Approaching Approval

I covered CTI BioPharma (CTIC) several times in the last few years. CTIC is a developer of cancer therapeutics. It has a long and challenging history - see here. To quickly recap, pacritinib, their lead candidate, is targeting cytopenic myelofibrosis. They have a PDUFA date on Feb 28, 2022. The...

Avisol Capital Partners on Seeking Alpha | December 24, 2021

CTI BioPharma (NASDAQ:CTIC) Stock Passes Above Two Hundred Day Moving Average of $0.00

CTI BioPharma Corp. (NASDAQ:CTIC)s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.00 and traded as high as $2.34. CTI BioPharma shares last traded at $2.29, with a volume of 821,009 shares traded. Several research analysts recently issued []

Dakota Financial News | December 23, 2021

Wall Streets Take On CTI BioPharma Corp. (NASDAQ: CTIC) Stock.

CTI BioPharma Corp. (NASDAQ:CTIC) traded at $2.30 at close of the session on Tuesday, 12/21/21, made a downward move of -0.43% on its previous days price. Looking at the stock we see that its previous close was $2.31 and the beta (5Y monthly) reads 0.69 with the days price range being $2.26 $2.385. In Wall Streets Take On CTI BioPharma Corp. (NASDAQ: CTIC) Stock. Read More »

Stocks Register | December 22, 2021

CTI BioPharma Corp. (CTIC) Gains 2.21%, Causing Bears To Win

CTI BioPharma Corp. (NASDAQ:CTIC) has a beta value of 0.69 and has seen 1.53 million shares traded in the last trading session. The company, currently valued at $211.48M, closed the last trade at $2.31 per share which meant it gained $0.05 on the day or 2.21% during that session. The CTIC stock price is -78.79% CTI BioPharma Corp. (CTIC) Gains 2.21%, Causing Bears To Win Read More »

Marketing Sentinel | December 21, 2021

Read More 'CTIC' Stories Here

CTIC Price Returns

1-mo -19.51%
3-mo -23.55%
6-mo -16.46%
1-year -40.00%
3-year 94.12%
5-year -59.34%
YTD -20.16%
2021 -22.98%
2020 103.80%
2019 116.44%
2018 -72.76%
2017 -34.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7847 seconds.